ConductScience.org, home

Paper36934257

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.

Amaro A and 23 others. J Exp Clin Cancer Res, 2023. Cited by 31 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Papers, record 36934257. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36934257

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.
PubMed
Journal
J Exp Clin Cancer Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
2.52
iCite
Revised in PubMed
2026-01-27
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Amaro AAdriana
2Reggiani FFrancesco
3Fenoglio DDaniela
4Gangemi RRosaria
5Tosi AAnna
6Parodi AAlessia
7Banelli BBarbara
8Rigo VValentina
9Mastracci LLuca
10Grillo FFederica
11Cereghetti AAlessandra
12Tastanova AAizhan
13Ghosh AAdhideb
14Sallustio FFabio
15Emionite LLaura
16Daga AAntonio
17Altosole TTiziana
18Filaci GGilberto
19Rosato AAntonio
20Levesque MMitchell

Source PubMed

See all 24 authorsDownload CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Myeloid-Derived Suppressor CellsMajor topic
MelanomaMajor topic
Animals
Mice
CTLA-4 Antigen
T-Lymphocytes, Regulatory
Killer Cells, Natural
Tumor Microenvironment
Azacitidine

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
21073Associazione Italiana per la Ricerca sul CancroPubMed
21073Associazione Italiana per la Ricerca sul CancroPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02608437A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma PatientsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References83

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121436444Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science2011https://conductscience.org/library/papers/21436444PubMed
219118225Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival.Eur Respir J2009https://conductscience.org/library/papers/19118225PubMed
333767177Targeting macrophages in cancer immunotherapy.Signal Transduct Target Ther2021https://conductscience.org/library/papers/33767177PubMed
431897157Influence of demethylation on regulatory T and Th17 cells in myelodysplastic syndrome.Oncol Lett2020https://conductscience.org/library/papers/31897157PubMed
526027431Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med2015https://conductscience.org/library/papers/26027431PubMed
617096021TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells.J Invest Dermatol2007https://conductscience.org/library/papers/17096021PubMed
728272106M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.Melanoma Res2017https://conductscience.org/library/papers/28272106PubMed
828187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
922368280Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection.J Leukoc Biol2012https://conductscience.org/library/papers/22368280PubMed
1035550530CD39 - A bright target for cancer immunotherapy.Biomed Pharmacother2022https://conductscience.org/library/papers/35550530PubMed
1131548600The emerging role of epigenetic therapeutics in immuno-oncology.Nat Rev Clin Oncol2020https://conductscience.org/library/papers/31548600PubMed
1211849319Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms.Immunology2002https://conductscience.org/library/papers/11849319PubMed
1324478339Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays.Bioinformatics2014https://conductscience.org/library/papers/24478339PubMed
1434795289Combination of epigenetic regulation with gene therapy-mediated immune checkpoint blockade induces anti-tumour effects and immune response in vivo.Nat Commun2021https://conductscience.org/library/papers/34795289PubMed
159521319Dendritic cells and the control of immunity.Nature1998https://conductscience.org/library/papers/9521319PubMed
1615611321PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.Int Immunol2005https://conductscience.org/library/papers/15611321PubMed
1734265363Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.Life Sci2021https://conductscience.org/library/papers/34265363PubMed
1825403716Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.Cancer Immunol Res2015https://conductscience.org/library/papers/25403716PubMed
1928447602Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer.Nat Commun2017https://conductscience.org/library/papers/28447602PubMed
2034066538Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28- T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34066538PubMed

See all 83 referencesDownload CSV of references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
42649503Current and future therapies for triple-negative breast cancer.J Hematol Oncol2026https://conductscience.org/library/papers/42649503PubMed
42500571Epigenetic Modulators and Immunotherapy in Malignant Melanoma.Oncol Res2026https://conductscience.org/library/papers/42500571PubMed
42439659
Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence.
Cells2026https://conductscience.org/library/papers/42439659PubMed
42435177Epigenetic Targeting in Myeloid Malignancies.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435177PubMed
42426902Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications.J Hematol Oncol2026https://conductscience.org/library/papers/42426902PubMed
42194057Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy.Biomolecules2026https://conductscience.org/library/papers/42194057PubMed
41930165Epigenetics of Malignant Melanoma: Mechanisms, Diagnostic Approaches and Therapeutic Applications.Oncol Res2026https://conductscience.org/library/papers/41930165PubMed
41797904Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response.iScience2026https://conductscience.org/library/papers/41797904PubMed
41684028A New Complexity Layer: DNA Methylation and the Predictive Impact of Epigenetic Tests.Int J Mol Sci2026https://conductscience.org/library/papers/41684028PubMed
41550427The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer.Cancer Heterog Plast2025https://conductscience.org/library/papers/41550427PubMed
41541220Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy.Neurooncol Adv2026https://conductscience.org/library/papers/41541220PubMed
41294748Cancer and Aging Biomarkers: Classification, Early Detection Technologies and Emerging Research Trends.Biosensors (Basel)2025https://conductscience.org/library/papers/41294748PubMed
40787072
The Systematic Comparison of Enhancer of Zeste Homolog-2-, Bromodomain-containing Proteins-, Histone Deacetylase-, and DNA-methyltransferase 1-inhibitors in a Syngeneic Murine Model of Melanoma Reveals Differential Anti-tumoral and Immunomodulatory Activities.
MedComm (2020)2025https://conductscience.org/library/papers/40787072PubMed
40682094Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40682094PubMed
40641934The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.Front Oncol2025https://conductscience.org/library/papers/40641934PubMed
40325471Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.Clin Epigenetics2025https://conductscience.org/library/papers/40325471PubMed
40317004Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/40317004PubMed
40038722The epigenetic hallmarks of immune cells in cancer.Mol Cancer2025https://conductscience.org/library/papers/40038722PubMed
40012016Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.Biomark Res2025https://conductscience.org/library/papers/40012016PubMed
39592582Epigenetics-targeted drugs: current paradigms and future challenges.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39592582PubMed

See all 23 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CDA978PubTator's text mininghttps://conductscience.org/library/genes/978NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
DNMT11786PubTator's text mininghttps://conductscience.org/library/genes/1786NCBI Gene
ICAM13383PubTator's text mininghttps://conductscience.org/library/genes/3383NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
GUADECITABINECHEMBL3544916Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3544916ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36934257

GET https://conductscience.org/api/papers/v1/36934257/authors?page=2